Modular Medical (MODD) 주식 개요는 의료 기기 회사로 운영되고 있습니다. 자세히 보기MODD 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6위험 분석수익이 USD$1m 미만입니다($0)지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.지난 5년간 매년 수익이 15.8% 감소했습니다.지난 1년 동안 주주가 크게 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기MODD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$4.15해당 없음내재 할인율Est. Revenue$PastFuture-27m12016201920222025202620282031Revenue US$1.0Earnings US$0.1AdvancedSet Fair ValueView all narrativesModular Medical, Inc. 경쟁사Jin Medical InternationalSymbol: NasdaqCM:ZJYLMarket cap: US$17.8mLifewardSymbol: NasdaqCM:LFWDMarket cap: US$18.0mIceCure MedicalSymbol: NasdaqCM:ICCMMarket cap: US$19.1mAdagio Medical HoldingsSymbol: NasdaqCM:ADGMMarket cap: US$18.7m가격 이력 및 성과Modular Medical 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$4.1552주 최고가US$30.0052주 최저가US$3.13베타-0.00151개월 변동-17.00%3개월 변동-71.89%1년 변동-83.41%3년 변동-86.95%5년 변동-99.03%IPO 이후 변동-91.22%최근 뉴스 및 업데이트공시 • Apr 23Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Apr 21Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $3.375 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $3.375 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 750,000 Price\Range: $4.5 Discount Per Security: $0.315 Transaction Features: Registered Direct OfferingNew Risk • Feb 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$35.0m market cap).공시 • Feb 27Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $12 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 23,571,007 Price\Range: $0.5091 Discount Per Security: $0.035637 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 23,571,007 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 23,571,007공시 • Feb 24Modular Medical, Inc. announced that it has received $0.35 million in fundingModular Medical, Inc. announced a private placement of promissory note for the gross proceeds of $350,000 from new lender James E. Besser on February 23, 2026. The note carry interest at the rate of 12% is payable on each draw down without regard to the draw down date or the date when interest is paid and maturity of March 25, 2026.New Risk • Feb 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$26m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$26m free cash flow). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$35.1m market cap).더 많은 업데이트 보기Recent updates공시 • Apr 23Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Apr 21Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $3.375 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $3.375 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 750,000 Price\Range: $4.5 Discount Per Security: $0.315 Transaction Features: Registered Direct OfferingNew Risk • Feb 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$35.0m market cap).공시 • Feb 27Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $12 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 23,571,007 Price\Range: $0.5091 Discount Per Security: $0.035637 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 23,571,007 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 23,571,007공시 • Feb 24Modular Medical, Inc. announced that it has received $0.35 million in fundingModular Medical, Inc. announced a private placement of promissory note for the gross proceeds of $350,000 from new lender James E. Besser on February 23, 2026. The note carry interest at the rate of 12% is payable on each draw down without regard to the draw down date or the date when interest is paid and maturity of March 25, 2026.New Risk • Feb 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$26m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$26m free cash flow). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$35.1m market cap).공시 • Jan 01Modular Medical Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RuleModular Medical, Inc. announced the Company received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), granting the Company’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5810(c)(3)(A) (the “Bid Price Rule”). The Company now has until June 29, 2026 to meet the requirement. If at any time prior to June 29, 2026, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule during the additional 180-day extension, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the relevant delisting determination to a Hearings Panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. The Company will continue to monitor the closing bid price of its common stock and evaluate its available options to regain compliance with the Bid Price Rule. Nasdaq’s extension notice has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the ticker symbol, “MODD”.공시 • Dec 31Modular Medical, Inc., Annual General Meeting, Jan 23, 2026Modular Medical, Inc., Annual General Meeting, Jan 23, 2026.New Risk • Dec 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$28.7m market cap).공시 • Dec 10+ 1 more updateModular Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.74747 million.Modular Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.74747 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,173,000 Price\Range: $0.385 Discount Per Security: $0.02695 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,086,500 Price\Range: $0.01 Discount Per Security: $0.0007공시 • Oct 07Modular Medical, Inc. Appoints David Bosshard as Head of International OperationsModular Medical, Inc. announced the appointment of David Bosshard as Head of International Operations. With two decades of expertise in scaling similar tubeless insulin delivery systems across Europe and beyond, Mr. Bosshard will drive Modular Medical's global strategy, leveraging his success in launching blockbuster products, such as Insulet's Omnipod and Ypsomed's YpsoPump, to position the Company for international growth in the rapidly expanding wearable diabetes technology sector. Key highlights of Bosshard's expertise and strategic impact: Led the successful launch of Insulet's Omnipod patch pump in Europe at Ypsomed AG from 2010 to 2017, growing the user base to nearly 70,000, while overseeing business operations for 13 country affiliates, including product distribution and marketing support; and as product area leader, spearheaded the 2017 launch of YpsoPump, driving CGM and AID integrations to deliver disruptive therapy outcomes; the system has since been distributed in over 20 countries across Europe, Australia and Canada.공시 • Jul 03Modular Medical Receives Nasdaq Non-Compliance Letter Regarding Minimum Bid Price RequirementOn June 30, 2025, Modular Medical, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on June 27, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until December 29, 2025, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Company’s Common Stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. In the event the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days provided it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and further provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice to the Company that its Common Stock will be subject to delisting. The above mentioned letter does not result in the immediate delisting of the Company’s Common Stock from the Nasdaq Capital Market. The Company is monitoring the closing bid price of its Common Stock and considering its available options in the event the closing bid price of the Company’s Common Stock remains below $1 per share.New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (67% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$40.4m market cap).공시 • Jun 22Modular Medical, Inc. Auditor Raises 'Going Concern' DoubtModular Medical, Inc. filed its Annual on Jun 20, 2025 for the period ending Mar 31, 2025. In this report its auditor, Farber Hass Hurley LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.New Risk • Jun 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$40.4m market cap).New Risk • Mar 24New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$46.4m market cap).공시 • Mar 21Modular Medical, Inc. announced that it expects to receive $11.9955 million in fundingModular Medical, Inc. announced a definitive subscription agreement with institutional and accredited investors for issuance of 6,247,656 units at a price of $1.92 per unit for gross proceeds of $11,995,499.52 on March 20, 2025. Each unit comprised of two common shares and one warrant. In connection with the private placement, the company will issue 12,495,312 shares and warrants to purchase 6,247,656 shares. Each warrant will be immediately exercisable and entitles the holder to acquire one share of common stock at an exercise price of $1.12 per share, for a period of four years following the closing of the offering. The private placement is expected to close on or about March 25, 2025, subject to the satisfaction of customary closing conditions. The transaction will include participation from certain officers and directors of the company intend to purchase a total of 374,478 units.New Risk • Feb 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$17m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$17m free cash flow). Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$16m net loss next year). Market cap is less than US$100m (US$46.2m market cap).공시 • Jan 27Modular Medical, Inc., Annual General Meeting, Feb 28, 2025Modular Medical, Inc., Annual General Meeting, Feb 28, 2025.Recent Insider Transactions • Dec 02Chief Executive Officer recently bought US$169k worth of stockOn the 27th of November, James Besser bought around 100k shares on-market at roughly US$1.69 per share. This transaction amounted to 69% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.Board Change • Dec 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Duane DeSisto was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 22Modular Medical, Inc. has filed a Follow-on Equity Offering.Modular Medical, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Prefunded Warrants Security Type: Equity Warrant공시 • Nov 08Modular Medical, Inc. Announces Results from a Successful GLP-1 Proof of Concept StudyModular Medical, Inc. announced successful results from its pre-clinical GLP-1 proof of concept study. As expected, none of the rapid acting GLP-1 arms matched the overall weight loss effect of the semaglutide arm. Notably, however, the semaglutide treated mice lost 8% of their body weight in the first two days of treatment as food and water intake was almost entirely absent. The rapid acting GLP-1 pump-treated mice had a much smoother initiation of treatment, as measured by body weight and food and water intake. While the full details of the study will be presented in subsequent communications, the topline data for weight loss in the diet-induced obese mouse model used is as set forth: The study was conducted across 5-arms. Dosing and corresponding body weight loss at 28 days were: Arm 1: Vehicle /no active drug 4.69%; Arm 2: 30 mcg basal with 20 mcg bolus once daily 13.82%; Arm 3: 50 mcg basal only 13.66%; Arm 4: 50 mcg basal with 20 mcg bolus once daily 17.09%; Arm 5: Semaglutide bolus daily 24.9% (8% in first 2 days).공시 • Sep 11Modular Medical, Inc. Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the Modd1 PlatformModular Medical, Inc. announced an update on its proof-of-concept study in a high-fat diet-induced obese (‘DIO’) mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. The Company has finalized its protocol for the proof-of concept study, which is now expected to commence in October 2024 with data readout in November 2024. MODD will seek to determine whether an existing FDA approved short-acting peptide delivered from a pump platform can provide a more personalized and more tolerable solution for patients who found long acting GLP-1 drugs too difficult to tolerate, while delivering comparable glycemic control and weight loss, specifically for people with type 2 diabetes and obesity.공시 • Sep 05Modular Medical, Inc Announces FDA Clearance of the MODD1 Insulin PumpModular Medical, Inc. announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States. With its commercial manufacturing infrastructure substantially established, the Company anticipates the MODD1 should be available for sale in early 2025. Modular Medical will hold a conference call to discuss the clearance of the MODD1 pump, as well as next steps and milestones. Details for the conference call will be announced when available.Major Estimate Revision • Aug 28Consensus revenue estimates decrease by 40%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$1.18m to US$700.0k. EPS estimate increased from -US$0.725 to -US$0.46 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target up from US$5.00 to US$8.00. Share price rose 7.8% to US$1.80 over the past week.분석 기사 • Jul 16Here's Why Modular Medical (NASDAQ:MODD) Must Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • Jun 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$16m free cash flow). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Market cap is less than US$100m (US$45.9m market cap).New Risk • Feb 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Market cap is less than US$100m (US$27.5m market cap).공시 • Feb 16+ 1 more updateModular Medical, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.Modular Medical, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,090,910 Price\Range: $1.1 Discount Per Security: $0.077New Risk • Feb 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$16m free cash flow). Shareholders have been substantially diluted in the past year (95% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$27.0m market cap).공시 • Jan 09Modular Medical, Inc., Annual General Meeting, Feb 13, 2024Modular Medical, Inc., Annual General Meeting, Feb 13, 2024, at 08:00 Pacific Standard Time. Agenda: To elect seven directors; to approve the amendment of the Amended 2017 Equity Incentive Plan (the 2017 Plan) to increase the number of shares available for issuance by 3,000,000 shares; to approve an amendment of the Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares; to ratify the appointment of Farber Hass Hurley LLP as independent registered public accounting firm for the fiscal year ending March31, 2024; and to consider other business issues.공시 • Nov 24Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Nov 01Modular Medical, Inc. Updates Test Progress and Submission TimelineModular Medical, Inc. provided an update on its ongoing pre-submission testing and timeline for submission of its MODD-1 insulin pump (the "MODD-1") to the U.S. Food and Drug Administration ("FDA"). The Company has made substantial progress on completing many of the tests required for submission and now has results back from some of the longest lead time tests, including insulin stability and potential. Modular Medical believes the test results received from multiple third-party laboratory tests are sufficient for submission of the MODD1 to the FDA for clearance, subject to the completion of other ongoing tests and reports.분석 기사 • Oct 08Here's Why We're A Bit Worried About Modular Medical's (NASDAQ:MODD) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Recent Insider Transactions • Sep 03Director recently bought US$156k worth of stockOn the 31st of August, Morgan Frank bought around 146k shares on-market at roughly US$1.07 per share. This transaction increased Morgan's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.공시 • Jul 07Modular Medical, Inc. Announces Appointment of Duane DeSisto to its Board of DirectorsModular Medical, Inc. announced the appointment of medical device industry leader Duane DeSisto to its board of directors. Mr. DeSisto was previously President, CEO and Director of Insulet Corporation, developers of the OmniPod Insulin Management System, before retiring in 2014. Mr. DeSisto served as President and CEO of Insulet from 2001 to 2014, where he led the creation and commercial adoption of the Company's debut product, OmniPod, the world's first tubing-free disposable insulin pump. Under Mr. DeSisto, Insulet grew from an early-stage company to a market cap of more than $2 billion and was nationally recognized for its technology design and rapid growth, including being listed fourth on Forbes' Most Innovative Growth Companies in 2014 with five-year average sales growth of 47 percent. Prior to that, he served as Chief Financial Officer of AAI-Foster Grant and Zoll Medical Corporation.New Risk • Jul 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$13m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Market cap is less than US$100m (US$21.5m market cap).공시 • May 18Modular Medical, Inc. has completed a Composite Units Offering in the amount of $9.389999 million.Modular Medical, Inc. has completed a Composite Units Offering in the amount of $9.389999 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,408,450 Price\Range: $2.13 Discount Per Security: $0.1491분석 기사 • Mar 15Modular Medical (NASDAQ:MODD) Will Have To Spend Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...공시 • Jan 26Modular Medical, Inc. Provides Update on FDA Submission StrategyModular Medical, Inc. provided an update on its insulin pump product. In the process of assessing and optimizing materials and sterilization processes for its MODD-1 insulin pump (the "MODD-1"), the Company has made sufficient progress on the full commercial version of the product that it now believes that the use of this commercial version for pre-submission validation testing constitutes its best and most cost-effective path forward. The full commercial version was designed in partnership with a tier-1, medical product manufacturer, and the Company believes that this new version will address all prior material compatibility issues, improve cost of goods and usability, and reduce redundant testing of different versions of the MODD-1. Given the expected arrival time of key production equipment and the resulting timing of tests of both the equipment and the product itself, the Company now expects to make its submission to the U.S. Food and Drug Administration ("FDA") during the quarter ended December 31, 2023.공시 • Dec 21Modular Medical, Inc., Annual General Meeting, Jan 17, 2023Modular Medical, Inc., Annual General Meeting, Jan 17, 2023, at 08:00 Pacific Standard Time. Agenda: To consider and elect seven directors to hold office for a one year term and until each of successors are elected and qualified, to consider and approve the amendment of the Amended 2017 Equity Incentive Plan to increase the number of shares available for issuance by 2,000,000 shares, to consider and approve, on a non-binding advisory basis, the compensation of named executive officers, as disclosed in the accompanying Proxy Statement, to consider and recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of named executive officers, to consider and ratify the appointment of Farber Hass Hurley LLP as independent registered public accounting firm for the fiscal year ending March 31, 2023; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.공시 • Nov 29Modular Medical, Inc. Announces Update on Development of its Initial Insulin Pump ProductModular Medical, Inc. announced an update on the development of its initial insulin pump product. The Company has continued to make progress on the testing required for its 510(k) submission to the U.S. Food and Drug Administration (FDA) of its MODD1 insulin pump product. The Company has identified certain material in the pump device that was incompatible with the sterilization process utilized. As previously announced, this compatibility issue has delayed the Company's 510(k) submission timeline. The Company has identified replacement materials, which are being qualified for use in the product. Given the expected resolution of the compatibility issue, the Company now expects to make its submission to the FDA during the quarter ended June 30, 2023.분석 기사 • Nov 19We're Keeping An Eye On Modular Medical's (NASDAQ:MODD) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Steve Felsher was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 04Modular Medical Provides Product UpdateModular Medical, Inc. provided an update on its insulin pump product. The Company has successfully completed the majority of the tests and documentation required for its 510(k) submission with the U.S. Food and Drug Administration ("FDA") of its MODD1 insulin pump product. However, in one of its qualification tests, the Company experienced a materials/sterilization process compatibility issue, which has delayed the submission to the FDA. Tests are underway to identify a solution, and, if the product needs to undergo qualification for a new sterilization method, the submission timeline will experience further delays. The Company now expects to make its submission to the FDA between December 2022 and June 2023 and intends to provide further updates after the required additional testing has been completed. Progress on developing production manufacturing capability has been promising. The Company is in the process of transferring production to a tier 1 contract manufacturer located in North America as part of its efforts to shorten and onshore its supply chain. Currently, this project is both ahead of schedule and initial cost estimates are in line with or better than the Company's initial internal estimates. Key initiatives on manufacturability, parts list reduction, and materials cost reductions are in process.공시 • Jul 27Modular Medical, Inc. Appoints Kevin Schmid as Chief Operating OfficerModular Medical, Inc. announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabetes Management System, the Amgen Neulasta On Body Injector, and the Ferring Pharmaceutical LutrePulse System. His work ranged from concept and product development to scaling multi-million unit global supply chains and high volume manufacturing operations. He was most recently the Chief Executive Officer of Common Sensing, a designer and manufacturer of disposable injector pen dose monitoring and reporting technology. Common Sensing was sold to Bigfoot Biomedical in 2021. Mr. Schmid is a member of the board of directors of Eitan Medical, an Israel-based provider of connected infusion and wearable drug delivery solutions. He has held previous roles at the Stevanato Group and Bose Corporation.Seeking Alpha • Jul 26Modular Medical appoints Kevin Schmid as COOModular Medical (NASDAQ:MODD) has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Schmid brings 40 years of experience in medical devices for drug delivery and diabetes management and a background in high-volume manufacturing. He was most recently the CEO of Common Sensing.분석 기사 • Jul 22We Think Modular Medical (NASDAQ:MODD) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Steve Felsher was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Mar 21Modular Medical: Next Generation Insulin Pump DeveloperModular Medical develops insulin pumps for diabetes management. The Company plans to submit its MODD1 device for FDA marketing approval in Q2 and launch by year-end. The Company is targeting a $3 billion market with an unmet need in insulin injection therapy.공시 • Feb 27Modular Medical, Inc. Announces Executive ChangesModular Medical, Inc. announced that its board of directors has appointed James “Jeb” Besser as Chief Executive Officer. Besser, a company development and capital markets veteran, has served 23 years as managing member of Manchester Management LLC. Lynn Vos, the Company’s CEO since August of 2021, will remain on the board of directors of the Company and continue an active role in the marketing and commercialization strategy for the Company, as the Company focuses on preparing and submitting to the FDA a 510(k) application for its next generation MODD1 insulin pump. Before joining the Company, Besser, 46, has served 23 years as managing member of Manchester Management LLC. He brings with him 25 years of U.S. public equity and capital markets experience, with a focus in life sciences and technology. On February 23, 2022, Ellen O’Connor Vos informed the board of directors of the company, that she was resigning from her position as Chief Executive Officer of the Company, effective immediately.공시 • Feb 15Manchester Management Engages in Discussions with Modular MedicalOn February 14, 2022, Manchester Management Company, LLC announced that it has been and might continue to be in contact with members of Modular Medical, Inc.'s management, the Company's Board of Directors, other significant shareholders and others regarding alternatives that the Company could employ to maximize shareholder value.공시 • Feb 11+ 1 more updateModular Medical Common Stock Deleted from Other OTCModular Medical, Inc. Common Stock has been deleted from Other OTC effective from February 10, 2022, due to Market Center Change Listed on NASDAQ.Board Change • Feb 11High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Steve Felsher was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • May 13Modular Medical, Inc. announced that it has received $6.56 million in fundingModular Medical, Inc. (OTCPK:MODD) announced that it has entered into securities purchase agreement for private placement of unsecured convertible promissory notes for gross proceeds of $6,560,000 on May 11, 2021. The transaction included participation from existing investors for over 50% of amount, while company insiders, including members of management and the board of directors for 20% and rest is subscribed by new investors. The notes are unsecured obligations having a stated maturity date of 12 months from its issue. The notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the company fails to pay any amounts when due under a note, the interest rate increases to the greater of 16% or the maximum amount permitted by law. Each note may be prepaid at the company’s option during the first 270 calendar days following its issue, subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No notes may be prepaid in whole or in part after the trigger date. If the notes remain outstanding after the trigger date, the notes are convertible at a initial price of $2.87 per share. If the company completes an offering of its common shares or other securities in excess of $12,000,000 of gross proceeds, each note holder will be required to convert its adjusted note amount into the securities of such qualified capital raise. Adjusted Note Amount equals the product of the sum of all outstanding principal plus accrued but unpaid interest by 1.25. The company also issued 2,285,736 warrants exercisable at $8 per share for a period of 5 years from the trigger date. The company issued securities pursuant to exemption provided under Regulation D.공시 • Feb 23Modular Medical, Inc. announced that it has received $1.1 million in fundingOn February 22, 2021, Modular Medical, Inc. (OTCPK:MODD) closed the transaction. The company has raised $1,100,000 in the transaction from two investors.주주 수익률MODDUS Medical EquipmentUS 시장7D19.9%3.0%-0.8%1Y-83.4%-18.3%27.1%전체 주주 수익률 보기수익률 대 산업: MODD은 지난 1년 동안 -18.3%의 수익을 기록한 US Medical Equipment 산업보다 저조한 성과를 냈습니다.수익률 대 시장: MODD은 지난 1년 동안 27.1%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is MODD's price volatile compared to industry and market?MODD volatilityMODD Average Weekly Movement22.0%Medical Equipment Industry Average Movement8.6%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%안정적인 주가: MODD의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: MODD의 주간 변동성은 지난 1년간 15%에서 22%로 증가했습니다.회사 소개설립직원 수CEO웹사이트n/a54Jeb Besserwww.modularmedical.com는 의료 기기 회사로 운영되고 있습니다. 이 회사는 인슐린 펌프의 설계, 개발 및 상용화에 중점을 두고 있습니다. 또한 제1형 및 제2형 당뇨병용 패치 펌프인 MODD1도 제공합니다.더 보기Modular Medical, Inc. 기초 지표 요약Modular Medical의 순이익과 매출은 시가총액과 어떻게 비교됩니까?MODD 기초 통계시가총액US$21.37m순이익 (TTM)-US$26.78m매출 (TTM)n/a0.0x주가매출비율(P/S)-0.8x주가수익비율(P/E)MODD는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표MODD 손익계산서 (TTM)매출US$0매출원가US$0총이익US$0기타 비용US$26.78m순이익-US$26.78m최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-4.95총이익률0.00%순이익률0.00%부채/자본 비율0%MODD의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 18:36종가2026/05/21 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Modular Medical, Inc.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bruce JacksonBenchmark CompanySteven LichtmanOppenheimer & Co. Inc.
공시 • Apr 23Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Apr 21Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $3.375 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $3.375 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 750,000 Price\Range: $4.5 Discount Per Security: $0.315 Transaction Features: Registered Direct Offering
New Risk • Feb 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$35.0m market cap).
공시 • Feb 27Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $12 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 23,571,007 Price\Range: $0.5091 Discount Per Security: $0.035637 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 23,571,007 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 23,571,007
공시 • Feb 24Modular Medical, Inc. announced that it has received $0.35 million in fundingModular Medical, Inc. announced a private placement of promissory note for the gross proceeds of $350,000 from new lender James E. Besser on February 23, 2026. The note carry interest at the rate of 12% is payable on each draw down without regard to the draw down date or the date when interest is paid and maturity of March 25, 2026.
New Risk • Feb 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$26m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$26m free cash flow). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$35.1m market cap).
공시 • Apr 23Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Apr 21Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $3.375 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $3.375 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 750,000 Price\Range: $4.5 Discount Per Security: $0.315 Transaction Features: Registered Direct Offering
New Risk • Feb 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$35.0m market cap).
공시 • Feb 27Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $12 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $12 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 23,571,007 Price\Range: $0.5091 Discount Per Security: $0.035637 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 23,571,007 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 23,571,007
공시 • Feb 24Modular Medical, Inc. announced that it has received $0.35 million in fundingModular Medical, Inc. announced a private placement of promissory note for the gross proceeds of $350,000 from new lender James E. Besser on February 23, 2026. The note carry interest at the rate of 12% is payable on each draw down without regard to the draw down date or the date when interest is paid and maturity of March 25, 2026.
New Risk • Feb 19New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$26m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$26m free cash flow). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$35.1m market cap).
공시 • Jan 01Modular Medical Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RuleModular Medical, Inc. announced the Company received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), granting the Company’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5810(c)(3)(A) (the “Bid Price Rule”). The Company now has until June 29, 2026 to meet the requirement. If at any time prior to June 29, 2026, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule during the additional 180-day extension, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the relevant delisting determination to a Hearings Panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. The Company will continue to monitor the closing bid price of its common stock and evaluate its available options to regain compliance with the Bid Price Rule. Nasdaq’s extension notice has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the ticker symbol, “MODD”.
공시 • Dec 31Modular Medical, Inc., Annual General Meeting, Jan 23, 2026Modular Medical, Inc., Annual General Meeting, Jan 23, 2026.
New Risk • Dec 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$28.7m market cap).
공시 • Dec 10+ 1 more updateModular Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.74747 million.Modular Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.74747 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,173,000 Price\Range: $0.385 Discount Per Security: $0.02695 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,086,500 Price\Range: $0.01 Discount Per Security: $0.0007
공시 • Oct 07Modular Medical, Inc. Appoints David Bosshard as Head of International OperationsModular Medical, Inc. announced the appointment of David Bosshard as Head of International Operations. With two decades of expertise in scaling similar tubeless insulin delivery systems across Europe and beyond, Mr. Bosshard will drive Modular Medical's global strategy, leveraging his success in launching blockbuster products, such as Insulet's Omnipod and Ypsomed's YpsoPump, to position the Company for international growth in the rapidly expanding wearable diabetes technology sector. Key highlights of Bosshard's expertise and strategic impact: Led the successful launch of Insulet's Omnipod patch pump in Europe at Ypsomed AG from 2010 to 2017, growing the user base to nearly 70,000, while overseeing business operations for 13 country affiliates, including product distribution and marketing support; and as product area leader, spearheaded the 2017 launch of YpsoPump, driving CGM and AID integrations to deliver disruptive therapy outcomes; the system has since been distributed in over 20 countries across Europe, Australia and Canada.
공시 • Jul 03Modular Medical Receives Nasdaq Non-Compliance Letter Regarding Minimum Bid Price RequirementOn June 30, 2025, Modular Medical, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on June 27, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until December 29, 2025, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Company’s Common Stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. In the event the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days provided it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and further provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice to the Company that its Common Stock will be subject to delisting. The above mentioned letter does not result in the immediate delisting of the Company’s Common Stock from the Nasdaq Capital Market. The Company is monitoring the closing bid price of its Common Stock and considering its available options in the event the closing bid price of the Company’s Common Stock remains below $1 per share.
New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (67% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$40.4m market cap).
공시 • Jun 22Modular Medical, Inc. Auditor Raises 'Going Concern' DoubtModular Medical, Inc. filed its Annual on Jun 20, 2025 for the period ending Mar 31, 2025. In this report its auditor, Farber Hass Hurley LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
New Risk • Jun 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$40.4m market cap).
New Risk • Mar 24New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$46.4m market cap).
공시 • Mar 21Modular Medical, Inc. announced that it expects to receive $11.9955 million in fundingModular Medical, Inc. announced a definitive subscription agreement with institutional and accredited investors for issuance of 6,247,656 units at a price of $1.92 per unit for gross proceeds of $11,995,499.52 on March 20, 2025. Each unit comprised of two common shares and one warrant. In connection with the private placement, the company will issue 12,495,312 shares and warrants to purchase 6,247,656 shares. Each warrant will be immediately exercisable and entitles the holder to acquire one share of common stock at an exercise price of $1.12 per share, for a period of four years following the closing of the offering. The private placement is expected to close on or about March 25, 2025, subject to the satisfaction of customary closing conditions. The transaction will include participation from certain officers and directors of the company intend to purchase a total of 374,478 units.
New Risk • Feb 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$17m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$17m free cash flow). Shareholders have been substantially diluted in the past year (83% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$16m net loss next year). Market cap is less than US$100m (US$46.2m market cap).
공시 • Jan 27Modular Medical, Inc., Annual General Meeting, Feb 28, 2025Modular Medical, Inc., Annual General Meeting, Feb 28, 2025.
Recent Insider Transactions • Dec 02Chief Executive Officer recently bought US$169k worth of stockOn the 27th of November, James Besser bought around 100k shares on-market at roughly US$1.69 per share. This transaction amounted to 69% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.
Board Change • Dec 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Duane DeSisto was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 22Modular Medical, Inc. has filed a Follow-on Equity Offering.Modular Medical, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Prefunded Warrants Security Type: Equity Warrant
공시 • Nov 08Modular Medical, Inc. Announces Results from a Successful GLP-1 Proof of Concept StudyModular Medical, Inc. announced successful results from its pre-clinical GLP-1 proof of concept study. As expected, none of the rapid acting GLP-1 arms matched the overall weight loss effect of the semaglutide arm. Notably, however, the semaglutide treated mice lost 8% of their body weight in the first two days of treatment as food and water intake was almost entirely absent. The rapid acting GLP-1 pump-treated mice had a much smoother initiation of treatment, as measured by body weight and food and water intake. While the full details of the study will be presented in subsequent communications, the topline data for weight loss in the diet-induced obese mouse model used is as set forth: The study was conducted across 5-arms. Dosing and corresponding body weight loss at 28 days were: Arm 1: Vehicle /no active drug 4.69%; Arm 2: 30 mcg basal with 20 mcg bolus once daily 13.82%; Arm 3: 50 mcg basal only 13.66%; Arm 4: 50 mcg basal with 20 mcg bolus once daily 17.09%; Arm 5: Semaglutide bolus daily 24.9% (8% in first 2 days).
공시 • Sep 11Modular Medical, Inc. Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the Modd1 PlatformModular Medical, Inc. announced an update on its proof-of-concept study in a high-fat diet-induced obese (‘DIO’) mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. The Company has finalized its protocol for the proof-of concept study, which is now expected to commence in October 2024 with data readout in November 2024. MODD will seek to determine whether an existing FDA approved short-acting peptide delivered from a pump platform can provide a more personalized and more tolerable solution for patients who found long acting GLP-1 drugs too difficult to tolerate, while delivering comparable glycemic control and weight loss, specifically for people with type 2 diabetes and obesity.
공시 • Sep 05Modular Medical, Inc Announces FDA Clearance of the MODD1 Insulin PumpModular Medical, Inc. announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States. With its commercial manufacturing infrastructure substantially established, the Company anticipates the MODD1 should be available for sale in early 2025. Modular Medical will hold a conference call to discuss the clearance of the MODD1 pump, as well as next steps and milestones. Details for the conference call will be announced when available.
Major Estimate Revision • Aug 28Consensus revenue estimates decrease by 40%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$1.18m to US$700.0k. EPS estimate increased from -US$0.725 to -US$0.46 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target up from US$5.00 to US$8.00. Share price rose 7.8% to US$1.80 over the past week.
분석 기사 • Jul 16Here's Why Modular Medical (NASDAQ:MODD) Must Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • Jun 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$16m free cash flow). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Market cap is less than US$100m (US$45.9m market cap).
New Risk • Feb 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Market cap is less than US$100m (US$27.5m market cap).
공시 • Feb 16+ 1 more updateModular Medical, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.Modular Medical, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,090,910 Price\Range: $1.1 Discount Per Security: $0.077
New Risk • Feb 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$16m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$16m free cash flow). Shareholders have been substantially diluted in the past year (95% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$27.0m market cap).
공시 • Jan 09Modular Medical, Inc., Annual General Meeting, Feb 13, 2024Modular Medical, Inc., Annual General Meeting, Feb 13, 2024, at 08:00 Pacific Standard Time. Agenda: To elect seven directors; to approve the amendment of the Amended 2017 Equity Incentive Plan (the 2017 Plan) to increase the number of shares available for issuance by 3,000,000 shares; to approve an amendment of the Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares; to ratify the appointment of Farber Hass Hurley LLP as independent registered public accounting firm for the fiscal year ending March31, 2024; and to consider other business issues.
공시 • Nov 24Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.Modular Medical, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Nov 01Modular Medical, Inc. Updates Test Progress and Submission TimelineModular Medical, Inc. provided an update on its ongoing pre-submission testing and timeline for submission of its MODD-1 insulin pump (the "MODD-1") to the U.S. Food and Drug Administration ("FDA"). The Company has made substantial progress on completing many of the tests required for submission and now has results back from some of the longest lead time tests, including insulin stability and potential. Modular Medical believes the test results received from multiple third-party laboratory tests are sufficient for submission of the MODD1 to the FDA for clearance, subject to the completion of other ongoing tests and reports.
분석 기사 • Oct 08Here's Why We're A Bit Worried About Modular Medical's (NASDAQ:MODD) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Recent Insider Transactions • Sep 03Director recently bought US$156k worth of stockOn the 31st of August, Morgan Frank bought around 146k shares on-market at roughly US$1.07 per share. This transaction increased Morgan's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
공시 • Jul 07Modular Medical, Inc. Announces Appointment of Duane DeSisto to its Board of DirectorsModular Medical, Inc. announced the appointment of medical device industry leader Duane DeSisto to its board of directors. Mr. DeSisto was previously President, CEO and Director of Insulet Corporation, developers of the OmniPod Insulin Management System, before retiring in 2014. Mr. DeSisto served as President and CEO of Insulet from 2001 to 2014, where he led the creation and commercial adoption of the Company's debut product, OmniPod, the world's first tubing-free disposable insulin pump. Under Mr. DeSisto, Insulet grew from an early-stage company to a market cap of more than $2 billion and was nationally recognized for its technology design and rapid growth, including being listed fourth on Forbes' Most Innovative Growth Companies in 2014 with five-year average sales growth of 47 percent. Prior to that, he served as Chief Financial Officer of AAI-Foster Grant and Zoll Medical Corporation.
New Risk • Jul 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$13m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Market cap is less than US$100m (US$21.5m market cap).
공시 • May 18Modular Medical, Inc. has completed a Composite Units Offering in the amount of $9.389999 million.Modular Medical, Inc. has completed a Composite Units Offering in the amount of $9.389999 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,408,450 Price\Range: $2.13 Discount Per Security: $0.1491
분석 기사 • Mar 15Modular Medical (NASDAQ:MODD) Will Have To Spend Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
공시 • Jan 26Modular Medical, Inc. Provides Update on FDA Submission StrategyModular Medical, Inc. provided an update on its insulin pump product. In the process of assessing and optimizing materials and sterilization processes for its MODD-1 insulin pump (the "MODD-1"), the Company has made sufficient progress on the full commercial version of the product that it now believes that the use of this commercial version for pre-submission validation testing constitutes its best and most cost-effective path forward. The full commercial version was designed in partnership with a tier-1, medical product manufacturer, and the Company believes that this new version will address all prior material compatibility issues, improve cost of goods and usability, and reduce redundant testing of different versions of the MODD-1. Given the expected arrival time of key production equipment and the resulting timing of tests of both the equipment and the product itself, the Company now expects to make its submission to the U.S. Food and Drug Administration ("FDA") during the quarter ended December 31, 2023.
공시 • Dec 21Modular Medical, Inc., Annual General Meeting, Jan 17, 2023Modular Medical, Inc., Annual General Meeting, Jan 17, 2023, at 08:00 Pacific Standard Time. Agenda: To consider and elect seven directors to hold office for a one year term and until each of successors are elected and qualified, to consider and approve the amendment of the Amended 2017 Equity Incentive Plan to increase the number of shares available for issuance by 2,000,000 shares, to consider and approve, on a non-binding advisory basis, the compensation of named executive officers, as disclosed in the accompanying Proxy Statement, to consider and recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of named executive officers, to consider and ratify the appointment of Farber Hass Hurley LLP as independent registered public accounting firm for the fiscal year ending March 31, 2023; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
공시 • Nov 29Modular Medical, Inc. Announces Update on Development of its Initial Insulin Pump ProductModular Medical, Inc. announced an update on the development of its initial insulin pump product. The Company has continued to make progress on the testing required for its 510(k) submission to the U.S. Food and Drug Administration (FDA) of its MODD1 insulin pump product. The Company has identified certain material in the pump device that was incompatible with the sterilization process utilized. As previously announced, this compatibility issue has delayed the Company's 510(k) submission timeline. The Company has identified replacement materials, which are being qualified for use in the product. Given the expected resolution of the compatibility issue, the Company now expects to make its submission to the FDA during the quarter ended June 30, 2023.
분석 기사 • Nov 19We're Keeping An Eye On Modular Medical's (NASDAQ:MODD) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Steve Felsher was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 04Modular Medical Provides Product UpdateModular Medical, Inc. provided an update on its insulin pump product. The Company has successfully completed the majority of the tests and documentation required for its 510(k) submission with the U.S. Food and Drug Administration ("FDA") of its MODD1 insulin pump product. However, in one of its qualification tests, the Company experienced a materials/sterilization process compatibility issue, which has delayed the submission to the FDA. Tests are underway to identify a solution, and, if the product needs to undergo qualification for a new sterilization method, the submission timeline will experience further delays. The Company now expects to make its submission to the FDA between December 2022 and June 2023 and intends to provide further updates after the required additional testing has been completed. Progress on developing production manufacturing capability has been promising. The Company is in the process of transferring production to a tier 1 contract manufacturer located in North America as part of its efforts to shorten and onshore its supply chain. Currently, this project is both ahead of schedule and initial cost estimates are in line with or better than the Company's initial internal estimates. Key initiatives on manufacturability, parts list reduction, and materials cost reductions are in process.
공시 • Jul 27Modular Medical, Inc. Appoints Kevin Schmid as Chief Operating OfficerModular Medical, Inc. announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabetes Management System, the Amgen Neulasta On Body Injector, and the Ferring Pharmaceutical LutrePulse System. His work ranged from concept and product development to scaling multi-million unit global supply chains and high volume manufacturing operations. He was most recently the Chief Executive Officer of Common Sensing, a designer and manufacturer of disposable injector pen dose monitoring and reporting technology. Common Sensing was sold to Bigfoot Biomedical in 2021. Mr. Schmid is a member of the board of directors of Eitan Medical, an Israel-based provider of connected infusion and wearable drug delivery solutions. He has held previous roles at the Stevanato Group and Bose Corporation.
Seeking Alpha • Jul 26Modular Medical appoints Kevin Schmid as COOModular Medical (NASDAQ:MODD) has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Schmid brings 40 years of experience in medical devices for drug delivery and diabetes management and a background in high-volume manufacturing. He was most recently the CEO of Common Sensing.
분석 기사 • Jul 22We Think Modular Medical (NASDAQ:MODD) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Steve Felsher was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Mar 21Modular Medical: Next Generation Insulin Pump DeveloperModular Medical develops insulin pumps for diabetes management. The Company plans to submit its MODD1 device for FDA marketing approval in Q2 and launch by year-end. The Company is targeting a $3 billion market with an unmet need in insulin injection therapy.
공시 • Feb 27Modular Medical, Inc. Announces Executive ChangesModular Medical, Inc. announced that its board of directors has appointed James “Jeb” Besser as Chief Executive Officer. Besser, a company development and capital markets veteran, has served 23 years as managing member of Manchester Management LLC. Lynn Vos, the Company’s CEO since August of 2021, will remain on the board of directors of the Company and continue an active role in the marketing and commercialization strategy for the Company, as the Company focuses on preparing and submitting to the FDA a 510(k) application for its next generation MODD1 insulin pump. Before joining the Company, Besser, 46, has served 23 years as managing member of Manchester Management LLC. He brings with him 25 years of U.S. public equity and capital markets experience, with a focus in life sciences and technology. On February 23, 2022, Ellen O’Connor Vos informed the board of directors of the company, that she was resigning from her position as Chief Executive Officer of the Company, effective immediately.
공시 • Feb 15Manchester Management Engages in Discussions with Modular MedicalOn February 14, 2022, Manchester Management Company, LLC announced that it has been and might continue to be in contact with members of Modular Medical, Inc.'s management, the Company's Board of Directors, other significant shareholders and others regarding alternatives that the Company could employ to maximize shareholder value.
공시 • Feb 11+ 1 more updateModular Medical Common Stock Deleted from Other OTCModular Medical, Inc. Common Stock has been deleted from Other OTC effective from February 10, 2022, due to Market Center Change Listed on NASDAQ.
Board Change • Feb 11High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Steve Felsher was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • May 13Modular Medical, Inc. announced that it has received $6.56 million in fundingModular Medical, Inc. (OTCPK:MODD) announced that it has entered into securities purchase agreement for private placement of unsecured convertible promissory notes for gross proceeds of $6,560,000 on May 11, 2021. The transaction included participation from existing investors for over 50% of amount, while company insiders, including members of management and the board of directors for 20% and rest is subscribed by new investors. The notes are unsecured obligations having a stated maturity date of 12 months from its issue. The notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the company fails to pay any amounts when due under a note, the interest rate increases to the greater of 16% or the maximum amount permitted by law. Each note may be prepaid at the company’s option during the first 270 calendar days following its issue, subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No notes may be prepaid in whole or in part after the trigger date. If the notes remain outstanding after the trigger date, the notes are convertible at a initial price of $2.87 per share. If the company completes an offering of its common shares or other securities in excess of $12,000,000 of gross proceeds, each note holder will be required to convert its adjusted note amount into the securities of such qualified capital raise. Adjusted Note Amount equals the product of the sum of all outstanding principal plus accrued but unpaid interest by 1.25. The company also issued 2,285,736 warrants exercisable at $8 per share for a period of 5 years from the trigger date. The company issued securities pursuant to exemption provided under Regulation D.
공시 • Feb 23Modular Medical, Inc. announced that it has received $1.1 million in fundingOn February 22, 2021, Modular Medical, Inc. (OTCPK:MODD) closed the transaction. The company has raised $1,100,000 in the transaction from two investors.
